VISION AND VALUE

CDP Consulting has developed solid foundations to manage these projects, at both national and European level, as evidenced by the experiences developed in recent years.

CDP Consulting

Our consultants have been trained in a company that has been developing clinical trials in the most diverse and complex therapeutic areas (from haematological oncology to rare diseases) for 16 years.
Working with the most important opinion leaders and stakeholders, they have been able to evolve the consulting projects and services we offer, to ensure we are always up-to-date and responsive to the continuous, rapid changes in the needs and rules of the market and of our customers.

Value

As in all markets, even in the Pharmaceutical and Medical Device sector, “data” are key when it comes to demonstrating the value of a drug, therapy, technology or device. The clinical data that matures from a Clinical Study then needs experts who disseminate it, raise awareness, give value both when the goal is to build a dossier for a registration, a scientific publication or a pharmacoeconomic document or a training project.

Mission

In all these areas, CDP Consulting seeks to guide the processes/projects, ensuring quality and precision which, with the right stakeholders, enable us to achieve our customers’ objectives. The perception of value by our customers’ target market will ensure a convinced, lasting choice of the product around which we work. Based on scientific reasoning, but also of the creation of a solid partnership between the stakeholder and the Company.

Consultancy “icona” Value “icona” Objectives

SPHERE OF COMPETENCE AND TARGET MARKET

CDP Consulting deals with the management and coordination of end-to-end projects in various fields and therapeutic areas of Life Science, putting its ideas, experience, method and relationships at the service of companies.

Allergology

Cardiology

Dermatology

Hematology

Gastroenterology

Gynecology

Infectious disease

Rare diseases

Laboratory medicine

Neurology

Oncology

Pulmonology

Psychiatry

Rheumatology

Urology

We focus on pharmaceutical and medical device companies in which our contacts are the medical, market access or sale and marketing managers, as well as scientific associations, study groups and hospitals and regional components.

Clinical stakeholders
Health management
Administrative stakeholders
Hospital pharmacists
Patient associations
Nurses/Case managers

Ideas “icona” Experience “icona” Method “icona” Relationships

METHOD AND PROJECTS

Icon Objectives

Thanks to its vision and experience gained over the years, CDP Consulting:

Icon Supports the customer in entering new therapeutic markets and in launching new products
Icon Creates awareness on topics of interest to the Sponsor
Icon Strengthens the Company’s relationship with key opinion leaders
Icon Supports the positioning of a product in the reference market
Icon Revitalises the life cycle of mature products

Icon Methodologies applied

Depending on the objectives set, CDP Consulting adopts various methodologies including:

Icon Consensus Conference
Icon Delphi Conferences
Icon Systematic literature review
Icon Critical literature analysis
Icon Benchmarking analysis

Icon Output

Thanks to the strict implementation of the methodologies and the skills of the stakeholders involved, all our projects lead to the production of different types of output:

Icon Recommendations
Icon Guidelines
Icon Expert Opinion Paper
Icon Consensus Paper
Icon Position Paper
Icon Patient Journey
Icon HTA Report
Icon Scientific publications
Icon Pharmacoeconomics publications

Icon Patient Journey

Patient Journeys (PJs) aim to define the best journey that the Patient should take in terms of diagnosis, therapy and follow-up. These are built with the involvement of all the stakeholders, who interact with the Patient/Caregiver during the illness. Designing a new journey or optimising the current one always originates from analysing the critical issues and checking what can be done to improve them. This discussion leads to draft statements of all the steps in the process, which are then discussed and endorsed at the Consensus Conference.
When is a Patient Journey needed?
Icon When the advent of a new drug makes it necessary to reformulate the patient’s journey in terms of a pathology
Icon When we are in a therapeutic area where such journeys have never been designed or are obsolete and no longer current

Icon Educational

The many education projects that CDP Consulting has come up with and developed over the years to ensure the objectives set with the customer are achieved in full vary in terms of topic, method, target and duration. In recent years, the period historically characterised by the impossibility of carrying out these activities in person has forced these projects to be implemented at a distance. CDP Consulting ensures it is always up to date when it comes to new technologies to support remote projects carried out at both national and European level, and this has enabled us to fully achieve the objectives set in terms of participation, quality and timing. From the discussion of clinical cases to the dissemination of Patient Journeys to web platforms that continuously offer the opportunity to train, interact and communicate, through opinion leaders, specialists also at international level, they nevertheless make it possible to complete training programs that are always fundamental to ensure ongoing scientific training for the target markets of interest.

Training “icona” Integration “icona” Communication

Publications

A Comprehensive Review on Copemyl

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A. Neurol Ther. 2017 Dec;6(2):161-173. doi: 10.1007/s40120-017-0079-3. Epub 2017 Jul 31.

Position paper of Italian rheumatologists on the use of biosimilar drugs

Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F, Meroni PL, Minghetti P, Sarzi-Puttini P, Ferraccioli G, Lapadula G. Clin Exp Rheumatol. 2015 Jan-Feb;33(1):1-4. Epub 2014 Nov…

Italian national consensus statement on management and pharmacological treatment of phenylketonuria

Alberto Burlina, Giacomo Biasucci, corresponding author Maria Teresa Carbone, Chiara Cazzorla, Sabrina Paci, Francesca Pochiero, Marco Spada, Albina Tummolo, Juri Zuvadelli, and Vincenzo Leuzzi, Orphanet J Rare Dis. 2021; 16:…

Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice

Lorenzo Pradelli, Tiziana Sinigaglia, Alberto Migliore, Giovanni Antonio Checchia, Francesco Franceschi, Bruno Frediani, Florenzo Iannone, Emilio Romanini. Ther Clin Risk Manag. 2021 May 28;17:507-530

The management of phenylketonuria in adult patients in Italy: a survey of six specialist metabolic centers

Alberto Burlina, Vincenzo Leuzzi, Marco Spada, Maria Teresa Carbone, Sabrina Paci, Albina Tummolo, Curr Med Res Opin. 2021 Mar;37(3):411-421. Epub 2021 Feb 1.

Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia

Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, Violi F; PReBRiC (Procedure-Related Bleeding Risk in Cirrhosis) group. Eur J Clin Invest. 2021 Jun;51(6):e13508. doi: 10.1111/eci.13508. Epub…

Clients

Here are the clients we have worked for:

Companies

IconAbbVie
IconAlfasigma
IconAmgen
IconAngelini
IconAstraZeneca
IconBiogen
IconBioMarin
IconBMS
IconCSL Behring
IconDompè
IconGilead
IconGlaxoSmithKline
IconHumanitas
IconIBSA
IconLilly

IconLundbeck
IconMSD
IconMylan
IconNestlé
IconNovartis
IconPfizer
IconSanofi
IconShionogi
IconSOBI
IconSorin Group
IconStallergenes
IconThermo Fisher Scientific
IconTeva
IconUCB
IconRoche

Scientific Associations

IconAIC – Onlus
IconAISF
IconAISP
IconANIRCEF
IconANNMAR
IconFIMMG
IconFIMP
IconIPERN
IconSIOMMMS
IconSIFO

IconSIMIT
IconSIMAST
IconSIMEU
IconSIMG
IconSIMFER
IconSIN
IconSIOT
IconSIOMMMS
IconSIR
IconSITI
IconSISC